[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
A phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy was performed for unresectable non-small-cell lung cancer. Chemotherapy consisted of a fixed dose of GEM (1,000 mg/m2) on day 1, 8 and an escalated dose of TXT (50, 60, 70 mg/m2) on day 8 every 21 days, > or = 2 courses. Nine patients were entered (each dose level: 3 patients). Leukopenia, neutropenia, GOT increase, GPT increase, anorexia, fatigue, fever, and alopecia occurred, but no dose-limiting toxicity was found at any dose level and no MTD was reached. The recommended dose for the phase II study is GEM 1,000 mg/m2 and TXT 70 mg/m2 with consideration of application to outpatients and continuing courses.